Oncology

Megan May, PharmD, BCOP, and Daneng Li, MD, review the efficacy and the pivotal trials for the somatostatin analogues in the treatment of NETs.

Experts in the management of NETs discuss how the treatment landscape has evolved.

Megan May, PharmD, BCOP, and Daneng Li, MD, discuss when patients with NETs should be considered for active surveillance vs treatment.

A panel of experts in neuroendocrine tumors provide a definition of the disease and the diagnosis methods.

Pipeline drugs, expanding pharmacist roles, and a focus on COVID-19 vaccination are trends to watch for in 2021.

This model focuses sharply on orphan diseases to better address the patient experience, outcomes, and requirements of each study.

The investigators performed a retrospective review of 215 patients age 65 years and older with TNBC or HER2+ breast cancer who underwent mastectomy from 2005 to 2020 at a single institution.

Investigators are set to begin testing sulfasalazine and auronofin, which are FDA-approved to treat rheumatoid arthritis, in cancer cell models.

Research over the past decade has shown that PV can be associated with a reduction in survival compared with age- and gender-matched population controls.

There are specific treatment options patients may qualify for depending on the cytogenetic or molecular abnormality detected.

Many rural areas identify with many barriers in their community, such as transportation, technology access, human factors, and the design of the health care model.

Recent data have shown alarmingly low rates of human papillomavirus (HPV) vaccine completion among children between 10 and 13 years of age.

One way of approaching the process of allowing patients to self-report their symptoms is through an electronic patient-reported outcomes (ePRO) system.

Although there have been many challenges and concerns during the pandemic, experts said there are also lessons to be learned and implemented once the pandemic is over.

The CDC recommends that patients with cancer and COVID-19 have a conversation with their health care provider or care team to discuss the individual level of risk based on the patient’s current condition, treatment, and the level of transmission within their community.

A supplemental new drug application has been submitted to the FDA for ivosidenib tablets (Tibsovo) as a potential therapeutic option for patients with previously treated, IDH1-mutated cholangiocarcinoma.

This activity is supported by educational grants from Seagen Inc., Daiichi Sankyo, and AstraZeneca.

Study findings illustrate the need for better communication between health care providers and patients experiencing concerns during the pandemic.

Directions in Oncology Pharmacy® talks to Gordon Vanscoy, PharmD, MBA, CACP, recently named a national Entrepreneur of the Year for 2020 by Ernst & Young.

As immunotherapies continue to show promise in more effectively combating several tumor types, many current strategies focus on ensuring the efficient delivery of active cytotoxic cells directly to tumors.

“Digital medicine and its regulation are constantly evolving, which is a great thing.”—Betsy Cernero, PharmD

Pharmacy Times® interviewed David Silverstein, JD, MS, a partner in Axinn’s Intellectual Property and FDA practice groups, on what may be coming to market in the rapidly growing cell therapy space, and the role pharmacists may play in this emerging landscape.

Addressing genomic differences and socioeconomic disparities is essential in order to address the higher incidences and mortality rates for prostate cancer among African American men.

Study findings suggest that enhanced cleaning and disinfecting policies are effective at reducing the spread of COVID-19.

This activity is supported by an educational grant from Incyte Corporation.

The FDA has granted a breakthrough therapy designation to tipifarnib for use in patients with recurrent or metastatic HRAS-mutated head and neck squamous cell carcinoma.

A more sensitive test capable of detecting heart function issues early in cancer treatment may be beneficial in preventing heart failure.

This activity is supported by an independent medical education grant from AcelRx Pharmaceuticals, Inc.